{"id":"lopinavir-ritonavir-simplification-strategy","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Lipid abnormalities"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":{"chemblId":"CHEMBL729","moleculeType":"Small molecule","molecularWeight":"628.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lopinavir/ritonavir is a fixed-dose combination of two HIV protease inhibitors; lopinavir inhibits viral protease and ritonavir acts as a pharmacokinetic booster. This simplification strategy aims to reduce the complexity of antiretroviral regimens, potentially through dose optimization or formulation changes, to enhance patient adherence and clinical outcomes in HIV-infected individuals.","oneSentence":"A treatment strategy that simplifies HIV management by optimizing the dosing or administration of lopinavir/ritonavir, a protease inhibitor combination, to improve adherence and reduce pill burden.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:57.197Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of antiretroviral therapy simplification strategy)"}]},"trialDetails":[{"nctId":"NCT02157311","phase":"PHASE3","title":"4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-07","conditions":"HIV-1 Infection","enrollment":100},{"nctId":"NCT00159224","phase":"PHASE4","title":"Induction-maintenance of Lopinavir/r in HIV-infected Subjects","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2005-04","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00994344","phase":"PHASE4","title":"Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-10","conditions":"HIV Infections","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kaletra monotherapy simplification strategy"],"phase":"marketed","status":"active","brandName":"Lopinavir/ritonavir simplification strategy","genericName":"Lopinavir/ritonavir simplification strategy","companyName":"Fundación Huésped","companyId":"fundaci-n-hu-sped","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A treatment strategy that simplifies HIV management by optimizing the dosing or administration of lopinavir/ritonavir, a protease inhibitor combination, to improve patient adherence and outcomes. Used for HIV-1 infection (as part of antiretroviral therapy simplification).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}